Previous 10 |
AUSTIN, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced plans to host its fourth qua...
Gainers: MacroGenics (NASDAQ: MGNX ) +129% . Snap (NYSE: SNAP ) +24% . Jason Industries (NASDAQ: JASN ) +23% . Bionano Genomics (NASDAQ: BNGO ) +16% . Proteostasis Therapeutics (NASDAQ: PTI ) +16% . Plantronics (NYSE: PLT ) +15% . Neon Therapeutics (NASDAQ: NTGN ) +15% . MaxLi...
Arlo Technologies (NYSE: ARLO ) -31% on Q4 earnings . More news on: Arlo Technologies, CCA Industries Inc, Catabasis Pharmaceuticals, Stocks on the move, Read more ...
Aeglea BioTherapeutics (NASDAQ: AGLE ) has priced public offering of 3.75M common stock at $8.00 per share, for expected gross proceeds of ~$60M. More news on: Aeglea BioTherapeutics, Healthcare stocks news, Read more ...
AUSTIN, Texas, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the pricing of an underwritt...
AUSTIN, Texas, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it intends to offer and...
News, Short Squeeze, Breakout and More Instantly...
Aeglea BioTherapeutics Inc. Company Name:
AGLE Stock Symbol:
NASDAQ Market:
Aeglea BioTherapeutics Inc. Website:
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD PR Newswire Company will begin trading on Nasdaq under trading sy...
2023-11-20 05:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a half-life extended anti-α4β...